HOBOKEN, NJ, USA and THE HAGUE, THE NETHERLANDS – June 9, 2023 – Wiley, one of the world’s largest publishers and a global leader in research and education, today announced that it will publish the ...

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and ...

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...

THE HAGUE, Netherlands, July 15, 2024 /PRNewswire/ -- The European Hematology Association (EHA) has undergone a remarkable transformation over the past two years, positioning itself as a future-ready ...

ATLANTA, GA - June 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases ...

Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021 - Accepted abstracts include new Phase 2 safety and tolerability data for CAEL-101 ...

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Inc. (HKEX:1228) , a China and US-based global biopharmaceutical company committed to the research, development and ...

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from ...

Toronto, Ontario--(Newsfile Corp. - May 15, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human ...

TORONTO, July 3, 2025 /CNW/ - Vertex Pharmaceuticals (VRTX) (Nasdaq: VRTX) recently announced positive longer-term data for Pr CASGEVY ® (exagamglogene autotemcel) from global ongoing pivotal clinical ...

An interim analysis of the phase 3 ALPINE study demonstrated that zanubrutinib has a superior response rate, improved progressive-free survival, and lower rate of atrial fibrillation/flutter compared ...